Fundraising FoxBioGeneration Ventures — 2017 Investments
4 investments dated 2017 · listed companies and verified rows first · show all
VarmX develops VMX-C001, a therapeutic medicine for treating severe bleeding in patients on Factor Xa anticoagulants and for emergency surgery settings.
BiotechHealthtechMedical Devices
Pieter Reitsma(Founder)inJohn Glasspool(Chief Executive Officer)in
Co-investorsInkefSound BioventuresYsios CapitalEICEQT Life SciencesUNIIQ+2 more
Mellon Medical manufactures a surgical instrument for abdominal wall closure featuring a double-pointed needle, ergonomic jaws, and atraumatic needle-suture combination.
HealthtechMedical DevicesRotterdam, NL
Co-investorsBOMThuja Capital
NorthSea Therapeutics is a clinical-stage biopharmaceutical company developing oral fatty acid-derived therapies for liver and metabolic diseases, including intestinal failure-associated liver disease (IFALD), severe hypertriglyceridemia, and MASH.
BiotechDigital HealthHealthtech
Co-investorsNew Science VenturesvenBio PartnersYsios CapitalBGVNovo HoldingsSofinnova Ventures+1 more
Scenic Biotech develops modifier therapy, a genetic medicine approach that targets secondary functions in the genome to neutralize the impact of disease-causing mutations.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtech
Co-investorsBioMedPartnersEIR VenturesInkefOxford Science Enterprises
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.